Business Context and Reporting Period
Cocrystal Pharma, Inc. filed this Form 8-K on March 19, 2019, to announce a 15-day extension under Rule 12b-25 for filing its Form 10-K for the year ended December 31, 2018. The extension is due to the finalization of accounting matters and the completion of audit procedures by the independent registered public accounting firm.
Key Financial Metrics
The filing provides preliminary, unaudited estimates for the fiscal year ended December 31, 2018:
- Total Loss: Approximately $63 million.
- Non-Cash Write-off: $54 million related to the remaining in-process research and development (IPR&D) intangible asset.
- Research and Development Expenses: Approximately $59 million, which includes the $54 million IPR&D write-off.
- Cash Flow, Debt, and Liquidity: The filing text does not provide clear values for operating cash flow, total debt, or liquidity positions.
Material Changes and Strategic Shifts
The Company abandoned compounds associated with the IPR&D asset acquired in its November 2014 merger with RFS Pharma. Consequently, the Company terminated its license agreement with Emory University regarding HCV inhibitors on December 6, 2018, as these compounds were no longer essential to the HCV program. The HCV program is now focused exclusively on the Company's internally created compound, CC-31244, in combination with approved drugs, aiming for ultra-short treatments of four to six weeks.
Outlook, Risks, and Contingencies
Management notes that the financial data presented is preliminary and subject to material change upon completion of the audit. The independent accounting firm has not audited or reviewed these figures. There are no future payments owed to Emory University following the termination of the license agreement. The primary risk highlighted is the potential for final financial results to differ materially from the current estimates.
Investor Verification Checklist
- Verify the final audited loss figure once the Form 10-K is filed.
- Confirm the exact composition of the $59 million R&D expense excluding the non-cash write-off.
- Review the updated cash position and runway in the final 10-K filing.
- Monitor the progress of the CC-31244 clinical trials and combination therapy strategy.